- Home
- NMRA vs DHY Comparison
NMRA vs DHY Comparison
Compare NMRA & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- DHY
- Stock Information
- Founded
- NMRA 2019
- DHY 1998
- Country
- NMRA United States
- DHY United States
- Employees
- NMRA N/A
- DHY N/A
- Industry
- NMRA
- DHY Finance/Investors Services
- Sector
- NMRA
- DHY Finance
- Exchange
- NMRA Nasdaq
- DHY Nasdaq
- Market Cap
- NMRA 234.5M
- DHY 220.7M
- IPO Year
- NMRA 2023
- DHY N/A
- Fundamental
- Price
- NMRA $2.08
- DHY $2.13
- Analyst Decision
- NMRA Buy
- DHY
- Analyst Count
- NMRA 8
- DHY 0
- Target Price
- NMRA $7.14
- DHY N/A
- AVG Volume (30 Days)
- NMRA 2.2M
- DHY 569.1K
- Earning Date
- NMRA 08-06-2025
- DHY 01-01-0001
- Dividend Yield
- NMRA N/A
- DHY 9.10%
- EPS Growth
- NMRA N/A
- DHY N/A
- EPS
- NMRA N/A
- DHY N/A
- Revenue
- NMRA N/A
- DHY N/A
- Revenue This Year
- NMRA N/A
- DHY N/A
- Revenue Next Year
- NMRA N/A
- DHY N/A
- P/E Ratio
- NMRA N/A
- DHY N/A
- Revenue Growth
- NMRA N/A
- DHY N/A
- 52 Week Low
- NMRA $0.61
- DHY $1.77
- 52 Week High
- NMRA $17.19
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- NMRA 70.06
- DHY 54.99
- Support Level
- NMRA $1.70
- DHY $2.10
- Resistance Level
- NMRA $2.85
- DHY $2.00
- Average True Range (ATR)
- NMRA 0.32
- DHY 0.02
- MACD
- NMRA 0.05
- DHY -0.00
- Stochastic Oscillator
- NMRA 58.08
- DHY 60.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.